仑卡奈单抗治疗者阿尔茨海默病血浆生物标志物的动态变化
这项纵向队列研究分析了接受仑卡奈单抗治疗的早期症状性阿尔茨海默病患者130种血浆蛋白的变化。130种标志物呈现正常化、过度矫正、反向和不变四种轨迹,其中34种显著变化;部分淀粉样蛋白和tau标志物部分正常化,而炎症和神经退行相关标志物(如TREM2和NPTXR)仍异常。
要点
- 仑卡奈单抗治疗与血浆淀粉样蛋白和tau标志物部分正常化相关。
- 炎症和神经退行相关标志物(如TREM2、NPTXR)呈反向轨迹或持续异常。
- 不同血浆标志物轨迹提示其未来可能用于监测治疗反应或判断预后。
核心结论
- 仑卡奈单抗治疗与阿尔茨海默病血浆标志物的动态、多向变化相关,淀粉样蛋白和tau部分正常化,但炎症和神经退行相关标志物仍异常。
研究设计与样本
- 纵向队列研究纳入197例已开始仑卡奈单抗输注的早期症状性阿尔茨海默病患者,并与1312例未治疗认知障碍对照和458例Aβ-无认知障碍对照比较。
- 仑卡奈单抗按10 mg/kg静脉输注,每2周一次,临床评估和采血约每6个月一次,最长2年。
主要发现
- 130种血浆蛋白被分为四种轨迹,其中34种在仑卡奈单抗组显著变化(错误发现率<0·05)。
- 正常化轨迹包括p-tau217、MAPT和GFAP,向Aβ-无认知障碍者浓度靠拢。
- 过度矫正轨迹包括淀粉样β肽,先向Aβ-无认知障碍者浓度靠拢后超越。
- 反向轨迹包括NPTXR、NRGN和TREM2,进一步偏离Aβ-无认知障碍者浓度。
- 不变轨迹包括NEFL和APOE。
临床怎么用
- 不同血浆标志物轨迹提示其可能分别用于监测治疗反应或判断预后,但尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-amyloid antibodies slow cognitive and functional decline in individuals with early symptomatic Alzheimer's disease, but few studies have examined changes associated with these treatments in plasma biomarkers linked to neurodegeneration. We analysed changes in a panel of 130 plasma proteins and their associations with conversion to amyloid PET negative status and cognitive changes in patients receiving lecanemab infusions as part of their clinical care. METHODS: This longitudinal cohort study included patients with early symptomatic Alzheimer's disease and positive amyloid biomarkers who were identified as candidates for biweekly lecanemab infusions based on the US Food and Drug Administration label and consented to blood collection at the Washington University Memory Diagnostic Center (St Louis, MO, USA) between July 17, 2023, and Oct 10, 2025. Lecanemab was administered as a 10 mg/kg intravenous infusion every 2 weeks. Patients underwent clinical assessments and blood draws approximately every 6 months over up to 2 years. Research participants enrolled at the Knight Alzheimer Disease Research Center (Knight ADRC; St Louis, MO, USA) between May 3, 1996, and Feb 27, 2025, and who did not receive anti-amyloid antibodies, were included as control groups (an amyloid β-negative [Aβ-] group without cognitive impairment and an untreated group with cognitive impairment). The primary outcome was change in plasma concentrations of protein biomarkers associated with Alzheimer's disease pathology with lecanemab treatment. Associations between plasma biomarker changes and number of lecanemab infusions were examined using regression and mixed-effects models, with adjustment for demographics. FINDINGS: The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants with cognitive impairment from the Knight ADRC cohort to form the untreated control group with cognitive impairment (n=1312). An additional 458 research participants formed the Aβ- control group without cognitive impairment. In the lecanemab group, the median patient age was 73 years (IQR 69-77); 104 (53%) were female and 93 (47%) were male; and most participants were White (187 [98%] of 190 with available data) and non-Hispanic (183 [97%] of 188 with available data). 130 biomarkers were classified into four distinct trajectories, with 34 showing significant changes (false discovery rate <0·05) in the lecanemab group. The trajectories were: normalising, with biomarkers shifting towards concentrations found in Aβ-individuals without cognitive impairment (eg, phosphorylated tau [p-tau]217, MAPT, and GFAP); overcorrecting, with biomarkers shifting towards and then beyond concentrations found in Aβ- individuals without cognitive impairment (eg, amyloid β peptides); opposite, with biomarkers shifting further from concentrations found in Aβ- individuals without cognitive impairment (eg, NPTXR, NRGN, and TREM2); and unchanged (eg, NEFL and APOE). INTERPRETATION: Lecanemab treatment was associated with dynamic, multidirectional changes across plasma biomarkers of Alzheimer's disease pathology, with partial normalisation of amyloid and tau biomarkers alongside abnormal concentrations of inflammatory and neurodegeneration-related biomarkers (eg, TREM2 and NPTXR), which might reflect an immune response to amyloid plaques and effects of treatment on neuronal and synaptic processes distinct from amyloid clearance. These divergent trajectories suggest that different biomarkers could eventually serve different clinical purposes, such as monitoring treatment response or informing patient prognosis, although further validation is needed. FUNDING: National Institute on Aging, Cure Alzheimer's Fund, and Washington University.
引用
- Mu R, Hofmann A, Gong K, et al. Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study. Lancet Neurol. 2026. PMID: 42785333. doi:10.1016/S1474-4422(26)00284-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。